Investor Presentaiton
8
MESSAGE FROM THE PRESIDENT
OF THE BOARD OF DIRECTORS
madica
DEAR SHAREHOLDERS, PARTNERS, CLIENTS AND COLLABORATORS: ON BEHALF OF THE BOARD OF
ADMINISTRATION AND THE MÉDICA SUR MANAGEMENT TEAM, I AM PLEASED TO PRESENT THIS REPORT
OF THE INSTITUTION'S PERFORMANCE, AS WELL AS THE PRINCIPAL STRATEGIC AND OPERATING
ACHIEVEMENTS IN THE YEAR.
In 2016, we continued on the path of expanding, modernizing and improving our
infrastructure in order to offer our patients medical excellence and human warmth
at fair prices.
In the medical field, by working together, the outstanding group of doctors and Médica
Sur continue to offer the highest quality of service to more than 15,000 patients
who were hospitalized in 2016. We performed 10,871 highly complex surgeries from
radiosurgery to liver transplants, as well as more than 2 million diagnostic tests. In
addition, 18,028 patients were attended in the Emergency Room.
The Quality still the trait that sets Médica Sur apart, sample of quality in our
services is the drop of the nosocomial infections annual rate (infections acquired
in a hospital), and the low mortality rate, which stood at 1.02 and 0.74 patients per
every 100 discharges, respectively. Likewise, the readmission rate was 3.9 per every
100 discharges. This reflects the institution's outstanding performance considering
both national and international standards.
Prevention is a regular part of our work. In this way, we have lowered the number of
infections in our facilities. Our patients' average length of stay stood at 2.95 days and
our average occupancy for the year was 72.0%.
As part of our strategy for the growth and enhancement of our infrastructure,
Laboratorio Médico Polanco and Laboratorios Clínicos de Puebla were acquired to
position us as the only health care provider with both hospitals and diagnostic units.
This has given us a competitive advantage over our main competitors, as well as
created synergy in biomedical research. Together, we have already published more
than 1,200 research papers.
This acquisition has broadened our presence and the diversity of services that we
currently offer in terms of clinical diagnosis and improved the range of services
available to our patients. With this transaction, we have added 76 health care
centers and two sample processing laboratories, one of which is a reference center
for processing high specialty tests. It has also enabled us to attend populations in
Mexico City, the State of Mexico, Morelos, Puebla, Queretaro and Tlaxcala, with the
most advanced laboratories in Mexico. Moreover, we now offer a wide variety of
diagnostic and other specialty imaging services in addition to clinical tests.
This operation is the largest ever made in Médica Sur's history. It will increase
the Group's consolidated sales by 35%, as well as its EBITDA, thus diversifying
our source of income by lowering our dependence on the Tlalpan Campus from
96% to 68%.
Furthermore, a letter of intent has been signed with Grupo Sordo Madaleno for the
sale of 47% of the total surface area, but only 21% of the building density, of a plot
adjacent to the Tlalpan Medical Complex. A mixed-use building with a shopping area
will be built on this land for the benefit of our patients and their family members by
offering them a better range of additional services to make their stay as pleasant
as possible. The remaining 25,000 m2 will still be used to continue enlarging the
medical project.
At Médica Sur, we are proud to have the first private Cancer Center in Mexico, which
celebrated its 20th anniversary in 2016. In early 2017, the center was reopened with
an updated design and a team of specialists that make every effort to provide better
alternatives throughout their patients' treatment.
Additionally, the refurbishment of the 6th, 7th and 8th floors of the hospital tower
was concluded in 2016. This will further the comfort of our patients by incorporating
the highest standards of quality and hygiene, and creating a friendly environment for
our patients and their family members.
In terms of financial performance, the Group's sales reached an accumulated
income of 2.59 billion pesos in 2016, which translates into: i) an operating profit of
210.7 million pesos with an operating margin of 8.1%; ii) a net income of 146.2 million
pesos with a net margin of 5.6% and iii) and an EBIDTA margin of 20.6%, or 535.9
million pesos.
During the year, there was a decrease in relevant metrics as a result of the
capitalization of the investment for the "Avanza" project (EPR). This did not represent
a cash flow and was replaced by technology with different capabilities. It should
be noted that if this decision had not been taken, a significant investment would
16 // ANNUAL REPORT
9View entire presentation